Report Overview

The UK Cystic Fibrosis (CF) Therapeutics market size stood at around USD 0.020 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Cystic Fibrosis (CF) is an inherited disease caused by a faulty version of a gene known as CFTR. The gene and the protein help control the movement of salt and water in and out of cells. When the gene is faulty, it can cause thicker mucus, thus lungs the major affected body organ; over time this thick mucus blocks and damages airways, leading to infections and making it hard to breathe. People with CF may also develop other problems, such as liver disease or CF-related diabetes (CFRD). Around 85%of people with CF also have difficulty digesting food.

According to UK Cystic Fibrosis Registry, in 2019, around 10655 CF patients have registered; more than 60% of the population are aged 16 or over and 21 is the median age of the UK CF population. Around 30% of the patient are diagnosed by New-born Screening (NBS). Of the 114 people with CF who died in 2019, the median age at death was 31 years old.



Market Growth Drivers

The prevalence of Cystic Fibrosis (CF) is considered a major driving factor in the UK market as around 10655 CF patients have been registered in 2019. Thus, the rising prevalence of respiratory problems, GI complications, and reproductive disorders in patients with CF is also expected to boost the demand for the treatment of disease during the forecast period.

The emergence of drugs that are targeting the defect in cells of people suffering from CF is enhancing market growth during the forecast period. In addition to this, many potential candidates are in their final stages of development and are projecting the growth of the market in the near future. For instance, Vertex Pharmaceuticals Inc. announced positive results from their phase III clinical study on inhaled mannitol indicated for the treatment of mucociliary clearance.

Along with this, the increasing incidence of chronic cough, blood in sputum, & collapsed lungs, and the technologically advanced devices used for various serious cases such as airway clearance techniques, mucous thinners, and others also propelling the CF therapeutics market during the forecast period.

The sudden outbreak of the COVID-19 pandemic brings the patient is at high risk of being infected by the virus. This, coupled with other various complications such as lung infections, inflammation of the pancreas, CF-related diabetes, and others strongly augmenting the CF market growth during the forecast period.